Drugs / BCD-263
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06112808 | May 2023 → Jan 2024 overdue | melanoma | Biocad | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06640530 | Mar 2024 → Dec 2025 overdue | cutaneous melanoma | Biocad | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCD-263 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06112808 ↗ |
| Route | Intravenous | “administered intravenously” NCT06112808 ↗ |